Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 | O43613 | 4/20 | 0.49 |
| ▸ | HCRTR2 | O43614 | 4/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | MMP8 | P22894 | 1/20 | 0.44 |
| ▸ | MMP12 | P39900 | 1/20 | 0.44 |
| ▸ | MMP13 | P45452 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | CASP1 | P29466 | 1/20 | 0.43 |
| ▸ | CASP7 | P55210 | 1/20 | 0.43 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19975052 | 1.00 | HCRTR1 (0.49) | HCRTR1HCRTR2KDM4EHSD17B10MAPT | |
| SCHEMBL21291444 | 0.86 | HCRTR1 (0.51) | HCRTR1HCRTR2ALDH1A1MCOLN3SMN1; SMN2 | |
| SCHEMBL29360904 | 0.86 | HCRTR1 (0.51) | HCRTR1HCRTR2ALDH1A1MCOLN3SMN1; SMN2 | |
| SCHEMBL19975023 | 0.83 | FKBP1A (0.48) | HCRTR1HCRTR2ALDH1A1MMP13MCOLN3 | |
| SCHEMBL5065638 | 0.83 | ALDH1A1 (0.59) | KDM4EMAPTALDH1A1HTTMCOLN3 | |
| SCHEMBL6926208 | 0.83 | ALDH1A1 (0.59) | KDM4EMAPTALDH1A1HTTMCOLN3 | |
| SCHEMBL8882067 | 0.83 | ALDH1A1 (0.59) | KDM4EMAPTALDH1A1HTTMCOLN3 | |
| SCHEMBL2704254 | 0.81 | HCRTR1 (0.70) | HCRTR1HCRTR2KDM4EHSD17B10ALDH1A1 | |
| SCHEMBL19975007 | 0.81 | HCRTR1 (0.52) | HCRTR1HCRTR2KDM4EHSD17B10ALDH1A1 | |
| SCHEMBL2704252 | 0.81 | HCRTR1 (0.70) | HCRTR1HCRTR2KDM4EHSD17B10ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220023311-A1 | HEPATITIS B CORE PROTEIN MODULATORS | ASSEMBLY BIOSCIENCES INC (US) | 2022-01-27 | — | — | US | disclosed |
| US-10987360-B2 | Hepatitis B core protein modulators | ASSEMBLY BIOSCIENCES, INC. (US) | 2021-04-27 | — | — | US | disclosed |
| US-20190255067-A1 | HEPATITIS B CORE PROTEIN MODULATORS | ASSEMBLY BIOSCIENCES INC (US) | 2019-08-22 | — | — | US | disclosed |
| EP-3512845-A1 | HEPATITIS B CORE PROTEIN MODULATORS | Assembly Biosciences, Inc. (US) | 2019-07-24 | — | — | EP | disclosed |
| WO-2018053157-A1 | HEPATITIS B CORE PROTEIN MODULATORS | ASSEMBLY BIOSCIENCES, INC. (US) | 2018-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10987360-B2 | Hepatitis B core protein modulators | HAVCR2, FABP1, MAVS | HCRTR1 4289/4885HCRTR2 4253/4885KDM4E 2469/4885 |
| US-20190255067-A1 | HEPATITIS B CORE PROTEIN MODULATORS | HAVCR2, FABP1, MAVS | HCRTR1 4289/4885HCRTR2 4253/4885KDM4E 2469/4885 |
| US-20220023311-A1 | HEPATITIS B CORE PROTEIN MODULATORS | HAVCR2, FABP1, MAVS | HCRTR1 4289/4885HCRTR2 4253/4885KDM4E 2469/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.